Harnessing multiple immune pathways to drive anti-tumor activity

“As a physician, my goal is to develop a therapy that all intended patients, and healthcare systems, can afford and deliver.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with Dr Frank Borriello, CEO, Alloplex Biotherapeutics, about a non-engineered, autologous approach to cancer immunotherapy. They discuss the ENLYST platform and multi-pathway immune cell activation, the SUPLEXA manufacturing process, comparability across variable autologous starting material, durability, and persistence, and the potential of decentralized manufacturing to improve patient access. They also explore how in vivo and ex vivo CAR-T fit into the evolving cell therapy landscape.